Are Neutrophil/Lymphocyte and Platelet/Lymphocyte Rates in Patients with Non-Small Cell Lung Cancer Associated with Treatment Response and Prognosis?

Abstract

Keywords: Neutrophil to lymphocyte ratio -non-small-cell lung cancer -platelet to lymphocyte ratio -prognosis

Albumin-globulin Ratio for Prediction of Long-term Mortality in Lung Adenocarcinoma Patients

“…Chronic inflammation markers (a part of the calculated globulins) play an important role in the proliferation, progression, development and metastasis of tumor cells (Mantovani et al, 2008;Gatta et al, 2012;Guo et al, 2013;Unal et al, 2013). They also significantly associated with angiogenesis, risk of reccurence and survival in patients with cancer.…”

Pretreatment Neutrophil/Lymphocyte Ratio as a Prognostic Aid in Colorectal Cancer

“…After that, emerging evidences from several studies have pointed out that NLR has a prognostic value in patients with pancreatic (Aliustaoglu et al, 2010), breast (Azab et al, 2012), lung (Kaya et al, 2013;Unal et al, 2013) and gastric (Jung et al, 2011) cancers. Recent literature has relatively fewer papers that focused on the significance of the pre-treatment NLR in CRC.…”

“…It is now becoming clear that the tumor microenvironment, which is largely orchestrated by inflammatory cells, is an essential participant in the neoplastic process, promoting proliferation, survival, and migration. For this reason many studies have been focused on the evidence of the role of inflammation in carcinogenesis recently (Waldner et al, 2006, Roxburgh et al, 2010Unal et al, 2013). Generally, studies described that lymphopenia means an impaired cell-mediated immunity, while neutrophilia is linked response to systemic inflammation (Zahorec et al, 2001).…”

The Neutrophil to Lymphocyte Ratio has a High Negative Predictive Value for Pathologic Complete Response in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

“…Lymphopenia is an independent prognostic factor for overall and progression-free survival in many cancers (Fogar et al, 2006;Ray-Coquard et al, 2009;Dou X et al, 2013). Elevated NLR has been associated with poor prognosis in many cancers, such as in pancreatic (Aliustaoglu et al, 2010), colorectal (Ozdemir et al, 2014), lung (Kaya et al, 2013;Unal et al, 2013), gastric (Jung et al, 2011) cancers and renal cell carcinoma (Fox et al, 2013). Elevated NLR at initial clinical presentation of BC was an independent factor for poor survival rate in breast cancer patients.…”